世界の線維筋痛症治療薬市場予測（～2028年）：シンバルタ（デュロキセチン）、サベラ（ミルナシプラン）、リリカ（プレガバリン）、パンクロニウム、その他

• 英文タイトル：Global Fibromyalgia Therapeutics Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

• レポートコード：GIR-22E8820 • 出版社/出版日：GlobalInfoResearch / 2022年5月 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

線維筋痛症治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界の線維筋痛症治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 線維筋痛症治療薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・シンバルタ（デュロキセチン）、サベラ（ミルナシプラン）、リリカ（プレガバリン）、パンクロニウム、その他 用途別セグメントは次のように区分されます。 ・病院、クリニック、その他 世界の線維筋痛症治療薬市場の主要な市場プレーヤーは以下のとおりです。 ・Pfizer、Eli Lilly、Actavis、Merck Sharp and Dohme、Daiichi Sankyo、Innovative Med Concepts、Meda、Meiji Seika、Switch Biotech、Theravance、Zynerba Pharmaceuticals、Tonix Pharmaceuticals Holding Corp. (TNXP)、Daiichi Sankyo、Forest Pharmaceuticals, Inc.、Boehringer Ingelheim GmbH、Pierre Fabre Mdicament 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、線維筋痛症治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な線維筋痛症治療薬メーカーの企業概要、2019年～2022年までの線維筋痛症治療薬の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な線維筋痛症治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別線維筋痛症治療薬の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの線維筋痛症治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での線維筋痛症治療薬市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および線維筋痛症治療薬の産業チェーンを掲載しています。 ・第13、14、15章では、線維筋痛症治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Eli Lilly、Actavis、Merck Sharp and Dohme、Daiichi Sankyo、Innovative Med Concepts、Meda、Meiji Seika、Switch Biotech、Theravance、Zynerba Pharmaceuticals、Tonix Pharmaceuticals Holding Corp. (TNXP)、Daiichi Sankyo、Forest Pharmaceuticals, Inc.、Boehringer Ingelheim GmbH、Pierre Fabre Mdicament ・メーカー別市場シェア ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：シンバルタ（デュロキセチン）、サベラ（ミルナシプラン）、リリカ（プレガバリン）、パンクロニウム、その他 ・用途別分析2017年-2028年：病院、クリニック、その他 ・線維筋痛症治療薬の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ ・線維筋痛症治療薬のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア ・線維筋痛症治療薬のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア ・線維筋痛症治療薬の南米市場規模2017年-2028年：ブラジル、アルゼンチン ・線維筋痛症治療薬の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Fibromyalgia Therapeutics Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Fibromyalgia Therapeutics Drugs market size is estimated to be worth US$ 2945.2 million in 2021 and is forecast to a readjusted size of USD 3308.4 million by 2028 with a CAGR of 1.7% during review period. Hospital accounting for % of the Fibromyalgia Therapeutics Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Cymbalta (Duloxetine) segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Fibromyalgia Therapeutics Drugs include Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, and Daiichi Sankyo, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Fibromyalgia Therapeutics Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Cymbalta (Duloxetine)
Savella (Milnacipran)
Lyrica (Pregabalin)
Pancuronium
Others
Market segment by Application can be divided into
Hospital
Clinic
Others
The key market players for global Fibromyalgia Therapeutics Drugs market are listed below:
Pfizer
Eli Lilly
Actavis
Merck Sharp and Dohme
Daiichi Sankyo
Innovative Med Concepts
Meda
Meiji Seika
Switch Biotech
Theravance
Zynerba Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. (TNXP)
Daiichi Sankyo
Forest Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Pierre Fabre Mdicament
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Fibromyalgia Therapeutics Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Fibromyalgia Therapeutics Drugs, with price, sales, revenue and global market share of Fibromyalgia Therapeutics Drugs from 2019 to 2022.
Chapter 3, the Fibromyalgia Therapeutics Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Fibromyalgia Therapeutics Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Fibromyalgia Therapeutics Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Fibromyalgia Therapeutics Drugs.
Chapter 13, 14, and 15, to describe Fibromyalgia Therapeutics Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Fibromyalgia Therapeutics Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Fibromyalgia Therapeutics Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Cymbalta (Duloxetine)
1.2.3 Savella (Milnacipran)
1.2.4 Lyrica (Pregabalin)
1.2.5 Pancuronium
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Fibromyalgia Therapeutics Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Fibromyalgia Therapeutics Drugs Market Size & Forecast
1.4.1 Global Fibromyalgia Therapeutics Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Fibromyalgia Therapeutics Drugs Sales in Volume (2017-2028)
1.4.3 Global Fibromyalgia Therapeutics Drugs Price (2017-2028)
1.5 Global Fibromyalgia Therapeutics Drugs Production Capacity Analysis
1.5.1 Global Fibromyalgia Therapeutics Drugs Total Production Capacity (2017-2028)
1.5.2 Global Fibromyalgia Therapeutics Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Fibromyalgia Therapeutics Drugs Market Drivers
1.6.2 Fibromyalgia Therapeutics Drugs Market Restraints
1.6.3 Fibromyalgia Therapeutics Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Fibromyalgia Therapeutics Drugs Product and Services
2.1.4 Pfizer Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly Fibromyalgia Therapeutics Drugs Product and Services
2.2.4 Eli Lilly Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Actavis
2.3.1 Actavis Details
2.3.2 Actavis Major Business
2.3.3 Actavis Fibromyalgia Therapeutics Drugs Product and Services
2.3.4 Actavis Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Merck Sharp and Dohme
2.4.1 Merck Sharp and Dohme Details
2.4.2 Merck Sharp and Dohme Major Business
2.4.3 Merck Sharp and Dohme Fibromyalgia Therapeutics Drugs Product and Services
2.4.4 Merck Sharp and Dohme Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Daiichi Sankyo
2.5.1 Daiichi Sankyo Details
2.5.2 Daiichi Sankyo Major Business
2.5.3 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Product and Services
2.5.4 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Innovative Med Concepts
2.6.1 Innovative Med Concepts Details
2.6.2 Innovative Med Concepts Major Business
2.6.3 Innovative Med Concepts Fibromyalgia Therapeutics Drugs Product and Services
2.6.4 Innovative Med Concepts Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Meda
2.7.1 Meda Details
2.7.2 Meda Major Business
2.7.3 Meda Fibromyalgia Therapeutics Drugs Product and Services
2.7.4 Meda Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Meiji Seika
2.8.1 Meiji Seika Details
2.8.2 Meiji Seika Major Business
2.8.3 Meiji Seika Fibromyalgia Therapeutics Drugs Product and Services
2.8.4 Meiji Seika Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Switch Biotech
2.9.1 Switch Biotech Details
2.9.2 Switch Biotech Major Business
2.9.3 Switch Biotech Fibromyalgia Therapeutics Drugs Product and Services
2.9.4 Switch Biotech Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Theravance
2.10.1 Theravance Details
2.10.2 Theravance Major Business
2.10.3 Theravance Fibromyalgia Therapeutics Drugs Product and Services
2.10.4 Theravance Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Zynerba Pharmaceuticals
2.11.1 Zynerba Pharmaceuticals Details
2.11.2 Zynerba Pharmaceuticals Major Business
2.11.3 Zynerba Pharmaceuticals Fibromyalgia Therapeutics Drugs Product and Services
2.11.4 Zynerba Pharmaceuticals Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
2.12.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Details
2.12.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Major Business
2.12.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Drugs Product and Services
2.12.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Daiichi Sankyo
2.13.1 Daiichi Sankyo Details
2.13.2 Daiichi Sankyo Major Business
2.13.3 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Product and Services
2.13.4 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Forest Pharmaceuticals, Inc.
2.14.1 Forest Pharmaceuticals, Inc. Details
2.14.2 Forest Pharmaceuticals, Inc. Major Business
2.14.3 Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Drugs Product and Services
2.14.4 Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Boehringer Ingelheim GmbH
2.15.1 Boehringer Ingelheim GmbH Details
2.15.2 Boehringer Ingelheim GmbH Major Business
2.15.3 Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Drugs Product and Services
2.15.4 Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Pierre Fabre Mdicament
2.16.1 Pierre Fabre Mdicament Details
2.16.2 Pierre Fabre Mdicament Major Business
2.16.3 Pierre Fabre Mdicament Fibromyalgia Therapeutics Drugs Product and Services
2.16.4 Pierre Fabre Mdicament Fibromyalgia Therapeutics Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Fibromyalgia Therapeutics Drugs Breakdown Data by Manufacturer
3.1 Global Fibromyalgia Therapeutics Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Fibromyalgia Therapeutics Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Fibromyalgia Therapeutics Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Fibromyalgia Therapeutics Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Fibromyalgia Therapeutics Drugs Manufacturer Market Share in 2021
3.5 Global Fibromyalgia Therapeutics Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Fibromyalgia Therapeutics Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Fibromyalgia Therapeutics Drugs Market Size by Region
4.1.1 Global Fibromyalgia Therapeutics Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Fibromyalgia Therapeutics Drugs Revenue by Region (2017-2028)
4.2 North America Fibromyalgia Therapeutics Drugs Revenue (2017-2028)
4.3 Europe Fibromyalgia Therapeutics Drugs Revenue (2017-2028)
4.4 Asia-Pacific Fibromyalgia Therapeutics Drugs Revenue (2017-2028)
4.5 South America Fibromyalgia Therapeutics Drugs Revenue (2017-2028)
4.6 Middle East and Africa Fibromyalgia Therapeutics Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Fibromyalgia Therapeutics Drugs Sales in Volume by Type (2017-2028)
5.2 Global Fibromyalgia Therapeutics Drugs Revenue by Type (2017-2028)
5.3 Global Fibromyalgia Therapeutics Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Fibromyalgia Therapeutics Drugs Sales in Volume by Application (2017-2028)
6.2 Global Fibromyalgia Therapeutics Drugs Revenue by Application (2017-2028)
6.3 Global Fibromyalgia Therapeutics Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Fibromyalgia Therapeutics Drugs Sales by Type (2017-2028)
7.2 North America Fibromyalgia Therapeutics Drugs Sales by Application (2017-2028)
7.3 North America Fibromyalgia Therapeutics Drugs Market Size by Country
7.3.1 North America Fibromyalgia Therapeutics Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Fibromyalgia Therapeutics Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Fibromyalgia Therapeutics Drugs Sales by Type (2017-2028)
8.2 Europe Fibromyalgia Therapeutics Drugs Sales by Application (2017-2028)
8.3 Europe Fibromyalgia Therapeutics Drugs Market Size by Country
8.3.1 Europe Fibromyalgia Therapeutics Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Fibromyalgia Therapeutics Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Fibromyalgia Therapeutics Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Fibromyalgia Therapeutics Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Fibromyalgia Therapeutics Drugs Market Size by Region
9.3.1 Asia-Pacific Fibromyalgia Therapeutics Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Fibromyalgia Therapeutics Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Fibromyalgia Therapeutics Drugs Sales by Type (2017-2028)
10.2 South America Fibromyalgia Therapeutics Drugs Sales by Application (2017-2028)
10.3 South America Fibromyalgia Therapeutics Drugs Market Size by Country
10.3.1 South America Fibromyalgia Therapeutics Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Fibromyalgia Therapeutics Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Fibromyalgia Therapeutics Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Fibromyalgia Therapeutics Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Fibromyalgia Therapeutics Drugs Market Size by Country
11.3.1 Middle East & Africa Fibromyalgia Therapeutics Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Fibromyalgia Therapeutics Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Fibromyalgia Therapeutics Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Fibromyalgia Therapeutics Drugs
12.3 Fibromyalgia Therapeutics Drugs Production Process
12.4 Fibromyalgia Therapeutics Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Fibromyalgia Therapeutics Drugs Typical Distributors
13.3 Fibromyalgia Therapeutics Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

---